JAK1

Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

Retrieved on: 
Monday, April 25, 2022
CSE, EMA, Protein, Pain, Myeloproliferative neoplasm, Woman, Hapten, Population, Paclitaxel, NASDAQ, Deaconess, Research, CAGR, Patient, Clinical trial, Ruxolitinib, PALM, European Medicines Agency, Carboplatin, Immune system, OTCQB, National Comprehensive Cancer Network, CTA, DRI, Ageing, Cryopreservation, Incidence, Abdomen, Stomach, News, Company, NCCN, Pelvis, Mutation, Ovarian cancer, CTI, Nausea, Fatigue, Cancer, Good, GMP, Bloating, Tissue, JAK1, Growth, NEWS, Industry, Prevalence, JAK2, Patent, Indigestion, Neoplasm, CTIC, Vaccine, Female, Birth control, Pharmaceutical industry, EU, Bevacizumab

Cancer remains undetected until the mutation spreads to the stomach and pelvis, a very advanced stage of ovarian cancer, which is fatal.

Key Points: 
  • Cancer remains undetected until the mutation spreads to the stomach and pelvis, a very advanced stage of ovarian cancer, which is fatal.
  • A report from Market Data Forecast projected that the size of the global ovarian cancer market is predicted to register a CAGR of 10.1% from 2022 to 2027 and that the increased prevalence of ovarian cancer worldwide are majorly accelerating the growth rate of the global ovarian cancer market.
  • Some of the other important reasons driving the growth of the ovarian cancer market are rising ovarian cancer prevalence, the launch of new medications and therapies, increased healthcare expenditure, and increased government funding.
  • Several ovarian cancer treatments are now in clinical trials and are likely to hit the market in the near future.

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate

Retrieved on: 
Friday, April 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, DAR, Principal, Motor neuron, Itch, Cough, Neck, Pharmacokinetics, ADC, Clinical research, Cancer, Monomethyl auristatin F, 5T4, Doctor of Philosophy, Head, Asana, Program, Neoplasm, Janus kinase, Pain, LLC, Safety, JAK3, JAK1, TYK2, ATP, SYK, PI3K, Neuron, JAK, Kinase, Atopic dermatitis, JAK2, Patient, Large-cell lung carcinoma, Respiratory disease, Vaccine, Pharmaceutical industry

ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.

Key Points: 
  • ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.
  • In preclinical cancer models, a single dose of ASN004 achieved complete and durable tumor regression leading to tumor-free survivors.
  • Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.
  • In a Phase 1b study in atopic dermatitis patients, topical application of ASN008 showed rapid onset of pruritus relief (NCT03798561).

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

Retrieved on: 
Monday, March 28, 2022
FAAD, Face, LinkedIn, Safety, Form 10-K, IGA, MA, Forward-looking statement, Skin, SEC, Doctor of Philosophy, Risk, Webcast, Ageing, Standard of care, Scalp, Q&A, Dermatology, EST, Psoriasis, Nail disease, Prevalence, Week, MD, Dermatitis, New, Review, Twitter, JAK1, Nasdaq, U.S. Securities and Exchange Commission, Mark (given name), GLOBE, Physician, NDA, FDA, Acne, Atopic dermatitis, Patient, Hair, Renewable energy, Pharmaceutical industry, Cosmetics, Risk management

This year will be transformational for Arcutis.

Key Points: 
  • This year will be transformational for Arcutis.
  • An archived replay of the webcast will be available on the Arcutis website following the event.
  • For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter .
  • We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Jyseleca® approved in Japan for ulcerative colitis

Retrieved on: 
Monday, March 28, 2022
Contraindication, EA, CET, Euronext, NASDAQ, Adult, Tablet, MTX, MHLW, Ulcerative colitis, Disease-modifying antirheumatic drug, Ministry of Health, Labour and Welfare, Medicine, Gilead Sciences, Safety, Rheumatoid arthritis, Interview, Inflammation, JAK1, Methotrexate, UC, Gilead, Physician, Product, Union, Degenerative disease, Fibrosis, Galapagos NV, Maintenance, RA, Eisai, European, Patient, Disease, Pharmaceutical industry, Health, Filgotinib

(Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan) and EA Pharma Co., Ltd. (Tokyo, Japan) today announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW), of a second indication for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis (UC).

Key Points: 
  • (Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan) and EA Pharma Co., Ltd. (Tokyo, Japan) today announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW), of a second indication for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis (UC).
  • The approval of this second indication for Jyseleca in Japan is based on data from the randomized, double-blind, placebo-controlled phase 2b/3 SELECTION study.
  • Jyseleca was approved in Japan in September 2020 for the treatment of rheumatoid arthritis (RA), including the prevention of structural joint damage, in patients who had inadequate response to conventional therapies.
  • Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply.

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

Retrieved on: 
Friday, March 18, 2022
Janus, Autoimmune disease, Degenerative disease, Translational medicine, Biotechnology, Cancer, Merck, CEO, Inflammation, TNF, Rheumatoid arthritis, Safety, JAK1, Ankylosing spondylitis, Methotrexate, Central nervous system disease, JAK, ZK, Atopic dermatitis, Patient, Johnson & Johnson, Partnership, Pharmaceutical industry, Fine chemical, Adalimumab, Simcere Pharmaceutical, Pfizer

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.

Key Points: 
  • HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.
  • Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product.
  • Published data of JAK1 inhibitor as treatment of ankylosing spondylitis have shown sufficient superiority of JAK1 inhibitor in a head-to-head study over Humira, the TNF targeting blockbuster.
  • LNK01001 is a highly selective JAK1 inhibitor with therapeutic potential for various autoimmune diseases.

CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

Retrieved on: 
Wednesday, March 2, 2022
Thrombocytopenia, Vera, Platelet, Patient, JAK2, FDA, CTIC, Ruxolitinib, Conference, Acquisition, JAK1, NASDAQ, CTI, Pharmaceutical industry

SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m.

Key Points: 
  • SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m.
  • CTI has one FDA-approved product VONJOTM (pacritinib), a JAK2 and IRAK1, that spares JAK1.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • VONJOTM is a trademark of CTI BioPharma Corp.

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

Retrieved on: 
Tuesday, March 1, 2022
Janus, Hematology, TYK2, Pneumonia, JAK3, Mount Sinai, Population, HIV disease progression rates, Heart, Webcast, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Peripheral edema, BAT, Bleeding, Toxicity, Fever, Haematopoiesis, Diarrhea, Associate professor, ID, CTI, JAK1, Cytokine, CTIC, Nausea, FMS, Vera, Disease, BD, CD135, DRI, Food, CSF1R, Acquisition, FLT3, Ruxolitinib, Caregiver, Cytopenia, Skin, FDA, Primary myelofibrosis, Platelet, Nasdaq, BID, Thrombocytopenia, Patient, Anemia, Pacritinib, Icahn School of Medicine at Mount Sinai, Oncology, JAK2, Pharmaceutical industry, Medicine

The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).

Key Points: 
  • The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).
  • As part of the accelerated approval, CTI is required to describe a clinical benefit in a confirmatory trial.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

Galapagos 2021 results set stage for future growth

Retrieved on: 
Thursday, February 24, 2022
Pharmacology, D, TYK2, Income, Annual report, Saitama (city), IPF, Inflammation, European Commission, Atopic dermatitis, Jaki, JAK1, Osteoarthritis, Sale, Safety, OA, Exercise, Observational study, PRAC, Leadership, EMA, Drug discovery, Pharmacovigilance, Patient, UC, Pharmaceutical industry, Medical device, Aquaculture, Renewable energy, Cryptocurrency, Filgotinib, Galápagos Islands

The results of Fidelta, including the impact of the 2021 sale, are presented as Net profit from discontinued operations in our consolidated income statements for the years 2021 and 2020.

Key Points: 
  • The results of Fidelta, including the impact of the 2021 sale, are presented as Net profit from discontinued operations in our consolidated income statements for the years 2021 and 2020.
  • We reported net sales of Jyseleca in 2021 amounting to 14.8 million, which reflects the sales booked by Galapagos after the country-by-country transition from Gilead.
  • We realized a net loss from continuing operations of 125.4million in 2021, compared to a net loss of 311.0million in 2020.
  • Galapagos expects to be able to publish its fully audited annual report for the full year 2021 on or around 24 March 2022.

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 22, 2022
Janus, GLOBE, Twitter, U.S. Securities and Exchange Commission, Atopic dermatitis, Psoriasis, Amgen, Research, COVID-19, Vitiligo, Therapy, Dermatology, JAK1, Company, Dermatitis, Corporation, G&A, Ageing, Review, New Drug Application, LinkedIn, Shanda, Skin, General counsel, FDA, R, Nasdaq, Patient, Scalp, NDA, PDE4, Standard of care, SEC, Bank, Pharmaceutical industry, Cosmetics, Medical device

We executed exceptionally well in 2021, delivering strong Phase 3 plaque psoriasis data, initiating three additional Phase 3 programs, and commencing our commercialization efforts.

Key Points: 
  • We executed exceptionally well in 2021, delivering strong Phase 3 plaque psoriasis data, initiating three additional Phase 3 programs, and commencing our commercialization efforts.
  • Patient enrollment continues in the pivotal Phase 3 trials in patients with atopic dermatitis (INTEGUMENT-1, INTEGUMENT-2, and INTEGUMENT-PED).
  • Topline data from each of INTEGUMENT-1 and INTEGUMENT-2, in subjects six years of age or older, are anticipated by the end of 2022.
  • General and administrative (G&A) expenses for the quarter ended December31, 2021 were $18.7 million compared to $6.7 million for the corresponding period in 2020.

TYK2 Kinase Inhibitors - Pipeline Insight 2022: Key Players Include Bristol-Myers Squibb, Oncostellae, Pfizer and Galapagos - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, Pharmaceutical, Health, Therapy, IBD, TYK2, Human, Atopic dermatitis, Diabetes, Ulcerative colitis, JAK, III, Janus kinase 1, Psoriasis, Lupus, ROA, Route of administration, Vitiligo, Hidradenitis suppurativa, JAK1, Crohn's disease, SLE, Inflammatory bowel disease, Clinical trial, RA, Bristol Myers Squibb, II, Rheumatoid arthritis, Administration, News, Route, Alopecia areata, Cancer, Discovery, Pharmaceutical industry, Tyrosine

The "TYK2 kinase inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TYK2 kinase inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • It further highlights the inactive pipeline products in this space
    Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.
  • The companies and academics are working to assess challenges and seek opportunities that could influence TYK2 Kinase Inhibitors R&D.
  • TYK2 Kinase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.